Device Trial Radar · NCT06716580
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Apr 1, 2025
Primary completion
Sep 1, 2027
Study completion Sep 1, 2030
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Beth Israel Deaconess Medical Center; Boston Medical Center; Massachusetts General Hospital
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Screening
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DNA (cfDNA) Assay
Conditions
- Lung Cancer
- EGFR Gene Mutation
Interventions
Circulating Tumor DNA (ctDNA) AssayDevice
Screening investigational blood test to test for EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. A positive or indeterminate investigational test will be followed up by CLIA verification of results. A positive or indeterminate CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Detection Rate of Non-Small Cell Lung CancerTime frame: 2 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Not yet recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Not yet recruiting
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.